Age-dependent prognostic value of KRAS mutation in metastatic colorectal cancer

References

• 1. Eklof V, Wikberg ML, Edin S et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br. J. Cancer 108(10), 2153–2163 (2013).
  Medline CASGoogle Scholar
• 2. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407), 330–337 (2012).
  MedlineGoogle Scholar
• 3. Obuch JC, Ahnen DJ. Colorectal cancer: genetics is changing everything. Gastroenterol. Clin. North Am. 45(3), 459–476 (2016).
  MedlineGoogle Scholar
• 4. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7(4), 295–308 (2007).
  Medline CASGoogle Scholar
• 5. Samowitz WS, Curtin K, Schaffer D et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol. Biomarkers Prev. 9(11), 1193–1197 (2000).
  Medline CASGoogle Scholar
• 6. Brink M, De Goeij AF, Weijenberg MP et al. K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands Cohort Study. Carcinogenesis 24(4), 703–710 (2003).
  Medline CASGoogle Scholar
• 7. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J. Natl Cancer Inst. 90(9), 675–684 (1998).
  Medline CASGoogle Scholar
• 8. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the “RASCAL II” study. Br. J. Cancer 85(5), 692–696 (2001).
  Medline CASGoogle Scholar
• 9. Brudvik KW, Kopetz SE, Li L et al. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 102(10), 1175–1183 (2015).
  Medline CASGoogle Scholar
• 10. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757–1765 (2008).
  Medline CASGoogle Scholar
• 11. Tosi F, Magni E, Amatu A et al. Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis. Clin. Colorectal Cancer 16(3), e153–e163 (2017).
  MedlineGoogle Scholar
• 12. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626–1634 (2008).
  Medline CASGoogle Scholar
• 13. Goffredo P, Utria AF, Beck AC et al. The prognostic impact of KRAS mutation in patients having curative resection of synchronous colorectal liver metastases. J. Gastrointest. Surg. 23(10), 1957–1963 (2019).
  MedlineGoogle Scholar
• 14. Benson AB 3rd, Venook AP, Cederquist L et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 15(3), 370–398 (2017).
  Medline CASGoogle Scholar
• 15. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25(Suppl. 3), iii1–iii9 (2014).
  MedlineGoogle Scholar
• 16. Arnold D, Lueza B, Douillard J-Y et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann. Oncol. 28(8), 1713–1729 (2017).
  Medline CASGoogle Scholar
• 17. Sheng H, Wei X, Mao M et al. Adenocarcinoma with mixed subtypes is a rare but aggressive histologic subtype in colorectal cancer. BMC Cancer 19(1), 1071 (2019).
  MedlineGoogle Scholar
• 18. Kneuertz PJ, Chang GJ, Hu C-Y et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA surgery 150(5), 402–409 (2015).
  MedlineGoogle Scholar
• 19. Basdanis G, Papadopoulos V, Michalopoulos A et al. Colorectal cancer in patients over 70 years of age: determinants of outcome. Tech. Coloproctol. 8(1), s112–s115 (2004).
  MedlineGoogle Scholar
• 20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45(6), 613–619 (1992).
  Medline CASGoogle Scholar
• 21. Massarweh NN, Chiang Y-J, Xing Y et al. Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. J. Clin. Oncol. 32(9), 942 (2014).
  MedlineGoogle Scholar
• 22. Hyngstrom JR, Hu C-Y, Xing Y et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann. Surg. Oncol. 19(9), 2814–2821 (2012).
  MedlineGoogle Scholar
• 23. Scott A, Goffredo P, Ginader T et al. The impact of KRAS mutation on the presentation and prognosis of non-metastatic colon cancer: an analysis from the National Cancer Database. J. Gastrointest. Surg. 24(6), 1402–1410 (2020).
  MedlineGoogle Scholar
• 24. Liang J, Kalady MF, Church J. Young age of onset colorectal cancers. Int. J. Colorectal Dis. 30(12), 1653–1657 (2015).
  MedlineGoogle Scholar
• 25. Berg M, Danielsen SA, Ahlquist T et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS ONE 5(11), e13978–e13978 (2010).
  MedlineGoogle Scholar
• 26. Cen P, Liu C, Du X. Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Ann. Oncol. 23(6), 1503–1511 (2012).
  Medline CASGoogle Scholar
• 27. Di Fiore F, Le Pessot F, Lamy A et al. KRAS mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer. J. Clin. Oncol. 25(Suppl. 18), 10502–10502 (2007).
  Google Scholar
• 28. Bouchahda M, Macarulla T, Spano J et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit. Rev. Oncol. Hematol. 67(3), 255–262 (2008).
  Medline CASGoogle Scholar
• 29. Jehn C, Böning L, Kröning H, Possinger K, Lüftner D. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br. J. Cancer 106(2), 274–278 (2012).
  Medline CASGoogle Scholar
• 30. Asmis T, Powell E, Karapetis C et al. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO. 17: a phase III trial of cetuximab versus best supportive care. Ann. Oncol. 22(1), 118–126 (2011).
  Medline CASGoogle Scholar
• 31. Bikov KA, Mullins CD, Hung A et al. Patterns of biologics use across treatment lines in elderly (age >65) medicare patients with metastatic colon cancer. Oncologist 21(6), 676 (2016).
  MedlineGoogle Scholar
• 32. Vargas GM, Sheffield KM, Parmar AD et al. Trends in treatment and survival in older patients presenting with stage IV colorectal cancer. J. Gastrointest. Surg. 18(2), 369–377 (2014).
  MedlineGoogle Scholar
• 33. Lee DW, Kim KJ, Han SW et al. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. Ann. Surg. Oncol. 22(1), 187–194 (2015).
  MedlineGoogle Scholar
• 34. Staudacher JJ, Yazici C, Bul V et al. Increased frequency of KRAS mutations in African Americans compared with Caucasians in sporadic colorectal cancer. Clin. Transl. Gastroenterol. 8(10), e124 (2017).
  Medline CASGoogle Scholar
• 35. Gabriel E, Attwood K, Al-Sukhni E et al. Age-related rates of colorectal cancer and the factors associated with overall survival. J. Gastrointest. Oncol. 9(1), 96–110 (2018).
  MedlineGoogle Scholar
• 36. White A, Joseph D, Rim SH et al. Colon cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer 123(Suppl. 24), 5014–5036 (2017).
  MedlineGoogle Scholar
• 37. Valeri L, Chen JT, Garcia-Albeniz X et al. The role of stage at diagnosis in colorectal cancer black-white survival disparities: a counterfactual causal inference approach. Cancer Epidemiol. Biomarkers Prev. 25(1), 83–89 (2016).
  MedlineGoogle Scholar
• 38. Alexander DD, Waterbor J, Hughes T et al. African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review. Cancer Biomark. 3(6), 301–313 (2007).
  MedlineGoogle Scholar
• 39. Roth AD, Tejpar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J. Clin. Oncol. 28(3), 466–474 (2010).
  Medline CASGoogle Scholar
• 40. Petrelli F, Tomasello G, Borgonovo K et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 3(2), 211–219 (2017).
  MedlineGoogle Scholar
• 41. Lerro CC, Robbins AS, Phillips JL, Stewart AK. Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann. Surg. Oncol. 20(6), 1759–1765 (2013).
  MedlineGoogle Scholar
• 42. Mallin K, Browner A, Palis B et al. Incident cases captured in the National Cancer Database compared with those in US population based central cancer registries in 2012–2014. Ann. Surg. Oncol. 26(6), 1604–1612 (2019).
  MedlineGoogle Scholar